张伯礼在普及中医药知识。 人民网记者 崔新耀摄 葛 根 虎 杖 杜 仲 杨华勇讲解盾构机工作原理。 郭 扬摄 具有自主知识产权的国产盾构机。 浙江大学供图 数据来源：中国科协 山东省青岛市莱西市河头店镇中心中学学生在体验VR项 目。 张进刚摄（人民视觉） 作为首个全国科普月的特别活动，讲座之后，张伯礼院士又把课堂搬到了校园西北角的天津中药植物园 （又称"如意药岭"），带着学生开启一场别开生面的科学漫步。 随时开展可见可触的科普 江苏省泰州市姜堰区淮海小学，学生与智能机器人互动。 周社根摄（人民视觉） 新修订的《中华人民共和国科学技术普及法》规定，每年9月为全国科普月。今年首个全国科普月的主 题为"科技改变生活 创新赢得未来"，聚焦宣传推广科技创新成果、弘扬科学精神和科学家精神、广泛 开展群众性科普等内容，多地推出的科普游园、科学漫步等活动受到公众欢迎。 本期"院士讲科普"推出全国科普月特别报道，让我们跟随中国工程院院士张伯礼打卡天津中药植物园、 跟着中国工程院院士杨华勇走进浙江大学高端装备研究院，感受科技改变生活的真切脚步，感受崇尚创 新的浓厚社会氛围。 ——编 者 在天津中药植物园—— 张伯礼院士教年轻人如 ...

9月13日是第26个世界急救日，主题为"急救与气候变化"。 当前，天气转凉，昼夜温差加大。气温的波动使血管频繁收缩扩张，增加了心血管疾病的发生风 险。 对于心血管急症，及时有效的救助至关重要。很多人可能首先会想到吃速效救心丸或硝酸甘油，但 也有不少人表示：如果心梗发作时没人帮忙，可通过大口呼吸、用力咳嗽的方式维持心脏供血，甚 至"自救"成功。 这种说法在社交媒体上广为流传，它究竟靠谱吗？ 心梗时"咳嗽自救"不可行 也许有人会认为，这种说法听起来有几分道理——咳嗽会增加胸腔压力，好像能把血液"挤"出来， 维持心脏供血。但这种理论在现实情境中几乎不可能发挥作用，原因如下： 首先，心肌梗死是因冠状动脉堵塞导致心肌缺血坏死，此时心脏泵血功能已严重受损。咳嗽产生的 胸腔压力变化虽能短暂提升血压，但无法疏通堵塞的血管，反而会增加心脏耗氧量，加速心肌细胞死 亡，还可能引发呕吐、肋骨骨折等二次伤害。 其次，心梗发作时，患者常出现剧烈胸痛、呼吸困难、意识模糊，此时基本无法进行"规律咳嗽"， 强行尝试极易错过黄金急救期。 因此，所谓"心梗发作时用力咳嗽能救命"的说法，不仅没有科学证据支持，还可能使人误判病情、 加重危险，进而造成 ...

Core Viewpoint - Aok shares highlighted the non-toxic and non-irritating properties of polyethylene glycol (PEG) products, emphasizing their wide applications in various industries, including pharmaceuticals and daily chemicals [1] Group 1: Product Characteristics - PEG products are characterized by good water solubility and compatibility with many organic components [1] - The products exhibit excellent lubricating, moisturizing, dispersing, adhesive, antistatic, and softening properties [1] Group 2: Industry Applications - Aok's PEG products have achieved large-scale applications in pharmaceutical excipients, raw materials for drugs, lithium battery new energy, and daily chemicals [1] - In the pharmaceutical sector, PEG is utilized in products such as Danshen dripping pills, rapid heart rescue pills, and injectables [1]

Core Viewpoint - Traditional Chinese medicine (TCM) is becoming an important force in promoting global health, with Tianyao Daren Tang Group actively participating in international cooperation and product innovation to spread TCM benefits beyond borders [1][2]. Group 1: Company Initiatives - Tianyao Daren Tang's flagship product, "Suxiao Jiuxin Wan," was registered as a prescription drug in Russia in 1997, marking it as the first Chinese patent medicine to receive such approval, which set a benchmark for TCM products entering international markets [1]. - Since 2017, Tianyao Daren Tang has established a stable partnership with Russian TCM companies, leading to the registration of various products, including the Dami Wan series and Jing Wan Hong as dietary supplements and cosmetics in Russia [2]. - The company emphasizes not only product export but also the promotion of TCM culture through international exhibitions and academic exchanges, enhancing local understanding and trust in TCM [2]. Group 2: Future Directions - Tianyao Daren Tang aims to deepen cooperation with countries in the Shanghai Cooperation Organization (SCO) in the field of TCM, focusing on clinical research, technology exchange, and mutual recognition of standards to contribute to a global health community [2][3].

Core Viewpoint - The company is committed to high-quality development and enhancing shareholder returns through the implementation of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2024 and 2025 [12] Group 1: Focus on Core Business - The company continues to concentrate resources on the traditional Chinese medicine sector, achieving a main industrial revenue of 2.645 billion yuan in the first half of 2025, a year-on-year increase of 0.87% [1] - Sales of the "Suxiao Jiuxin Wan" reached 1.128 billion yuan, up 5.45%, while "Qingyan Diban" sales surged by 52.28% to 289 million yuan [1] Group 2: Enhancing New Quality Productivity - The company has implemented unified internal control standards for medicinal materials, establishing 46 procurement standards that exceed the Chinese Pharmacopoeia [3] - The company has initiated the drafting of the "Tianyao Darentang Medicinal Material Quality Standards (2025)" and completed initial drafts for 100 varieties [3] - The company has launched several innovative products and completed various quality stability studies, including the successful entry of "Suxiao Jiuxin Wan" into a modern Chinese medicine technology innovation project [3] Group 3: Shareholder Returns - The company distributed a cash dividend of 1.28 yuan per 10 shares in July 2024, totaling 986 million yuan, and plans to implement the same dividend in July 2025 [4] - Since its listing in 2001, the company has distributed a total of 5.117 billion yuan in cash dividends, with an average dividend payout ratio of 50.69% [4] Group 4: Investor Communication and Transparency - The company has improved the readability of its announcements and actively engages in various investor communication activities, receiving an A-level rating for information disclosure in 2023-2024 [6] - The company has organized events for investors to experience its culture and products, enhancing shareholder engagement [6] Group 5: Governance and Compliance - The company is committed to updating internal regulations and enhancing investor protection, particularly for minority shareholders [8] - The company has established a special management approach for excess incentives to align the interests of key personnel with those of shareholders [9]

Core Viewpoint - The stock price of Darentang is reported at 45.77 yuan, reflecting a decline of 1.65% from the previous trading day, with a trading volume of 6.98 billion yuan [1] Group 1: Company Overview - Darentang primarily engages in the production and sales of traditional Chinese medicine and Western medicine, owning several well-known brands such as Darentang and Longshunrong [1] - The company's core products include traditional Chinese medicine varieties like Su Xiao Jiu Xin Wan and Qing Yan Di Wan [1] Group 2: Financial Performance - In the first half of 2025, the company's operating revenue decreased by 33.15% to 2.651 billion yuan [1] - Revenue from traditional Chinese medicine business was 2.425 billion yuan, down 20.81% year-on-year, while revenue from Western medicine business was 468 million yuan, down 24.86% year-on-year [1] - The net profit attributable to the parent company was 1.928 billion yuan, an increase of 193.08% year-on-year, but the non-recurring net profit decreased by 5.93% to 596 million yuan [1]

Core Viewpoint - The company is committed to enhancing quality and efficiency while providing returns to shareholders through its 2024 and 2025 action plans, focusing on core business areas and improving production capabilities [1][2]. Group 1: Focus on Core Business - The company aims to enhance brand strength, product quality, and service capabilities, achieving an industrial main revenue of 2.645 billion yuan in the first half of 2025, a year-on-year increase of 0.87%, with sales of the fast-acting heart-saving pill growing by 52.28% [1][2]. - The company has initiated a public welfare campaign for the fast-acting heart-saving pill and successfully hosted the 11th Traditional Chinese Medicine Material Base Sharing Conference [1]. Group 2: Enhancing Production Quality - The company has established 46 procurement standards for traditional Chinese medicine materials that exceed the Chinese Pharmacopoeia standards and is working on the "Quality Standards for Traditional Chinese Medicine Materials (2025)" [2]. - The company has launched several product innovations, including age-friendly product adaptations and the development of new products for sensitive skin, which were launched in July [2]. Group 3: Shareholder Returns - The company distributed a cash dividend of 12.80 yuan per 10 shares, totaling 986 million yuan, with a cumulative cash dividend of 5.117 billion yuan since its listing in 2001, reflecting an average dividend payout ratio of 50.69% [4]. - The company plans to continue enhancing shareholder returns while adhering to regulatory guidelines on cash dividends [4]. Group 4: Investor Communication - The company has improved its information disclosure practices, receiving an A-level rating for information disclosure for 2023-2024, and has organized various activities to enhance investor engagement [5]. - The company has opened new channels for shareholder participation in governance and feedback, including a dedicated email for the chairman [5]. Group 5: Governance and Compliance - The company has updated its governance policies to protect investor rights, particularly for minority shareholders, and has implemented new management systems [6]. - The company has introduced incentive programs for key personnel to align their interests with those of shareholders [6][8].

Core Viewpoint - The company, Darentang, reported a significant increase in net profit by 193% to 1.928 billion yuan, while revenue plummeted by 33.15% to 2.651 billion yuan, marking the third consecutive year of revenue decline [1] Financial Performance - Net profit surged to 1.928 billion yuan, primarily supported by the sale of key assets [1] - Revenue fell to 2.651 billion yuan, continuing a downward trend with projected declines of 0.33% and 11.14% for 2023 and 2024 respectively [1] - The sale of a 12% stake in Tianjin Schering Pharmaceutical generated a post-tax net gain of 1.308 billion yuan, significantly boosting net profit [1] - Excluding this asset sale, the adjusted net profit was only 596 million yuan, reflecting a year-on-year decline of 5.99% [1] Asset Management - The divestment of Tianjin Schering, a key profit contributor, raises concerns about the company's long-term cash flow stability [1] - The company has exited a partnership that previously provided nearly 25% of its investment income in 2023 [1] - Both asset sales were executed at a 35% premium, but market sentiment remains cautious regarding future cash flow [1] Product Performance - Traditional Chinese medicine accounts for 91.47% of the company's revenue, with "Suoxiao Jiuxin Wan" showing only a slight sales increase of 5.45% to 1.128 billion yuan [1] - The promising "Qingyan Diban" product saw a substantial increase of 52.28% to 289 million yuan, but its small scale limits its impact [1] Compliance and Quality Issues - The company has faced multiple quality compliance issues, including penalties for substandard products and GMP deficiencies reported by the FDA [2] - Complaints related to quality, marketing, and after-sales service have exceeded 20 since 2025 [2] - The company's "slimming strategy" has led to short-term financial gains but has also resulted in weakened revenue-generating capabilities and cash flow [2] Strategic Challenges - The company is experiencing a lack of new product development to replace declining sales from its flagship products [2] - The lengthy innovation cycle in traditional Chinese medicine poses challenges for immediate revenue recovery [2] - The need for a return to product innovation and compliance is emphasized as essential for sustainable growth [2]

Core Viewpoint - The financial report of traditional Chinese medicine company Darentang (600329.SH) reveals a paradox of declining revenue and soaring profits, raising concerns about its core product growth and innovation capabilities amid industry challenges [1] Financial Performance - Darentang reported a revenue of 2.651 billion yuan, a year-on-year decline of 33.15%, while net profit surged by 193.08% to 1.928 billion yuan [1] - The profit increase was largely driven by non-recurring gains from the sale of Tianjin Shike equity, contributing 1.332 billion yuan; excluding this, the adjusted net profit grew by only 12.86% to 596 million yuan [2] - The revenue drop was primarily due to the strategic divestment of the pharmaceutical commercial sector, which accounted for over 30% of revenue [2] Business Structure and Product Performance - The industrial segment showed resilience with a revenue of 2.645 billion yuan, a slight increase of 0.87%, compensating for the loss from the commercial sector [2] - Key products like Suoyao Jiuxin Wan generated sales of 1.128 billion yuan, up 5.45%, while Qingyan Dingwan saw a remarkable growth rate of 52.28%, reaching sales of 289 million yuan [2] R&D and Innovation Challenges - Despite a 31.94% increase in R&D spending to 61.55 million yuan, the output of innovative products remains limited, with only two national-level traditional Chinese medicines in the pipeline [3] - The company is attempting cross-industry innovation with the launch of "Shuyuan Anfu series" skincare products, but this segment currently contributes less than 5% to total revenue [3] Quality Control and Policy Environment - The year 2025 is significant for the traditional Chinese medicine industry, with new policies aimed at enhancing quality control [4] - Darentang has improved its self-sufficiency in core medicinal materials from 35% in 2023 to 48% in mid-2025, with a quality inspection pass rate of 99.7% [4] Brand and Channel Strategy - The company has intensified brand-building efforts, conducting over 200 promotional events and increasing the proportion of young consumers to 28% [5] - Channel expansion has been a focus, with the coverage of grassroots medical institutions rising from 62% to 71%, although this has led to increased sales costs [6] Market Outlook and Challenges - Analysts express concerns about Darentang's core competitiveness, highlighting three main challenges: slowing growth of key products, lagging innovation in drug development, and the need for the health business to achieve scale [7] - The company's future success will depend on the progress of innovative drug development, the maturity of the health business model, and the ability to offset rising costs through increased sales from expanded channels [7]

Core Viewpoint - Guohai Securities report indicates that Darentang's core product revenue is growing steadily, and the company is expected to have long-term growth potential [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 2.651 billion yuan, with industrial main revenue of 2.645 billion yuan, representing a year-on-year increase of 0.87% [1] - Sales revenue of the fast-acting rescue heart pill (including tax) reached 1.128 billion yuan, with a year-on-year growth of 5.45% [1] - Sales revenue of the throat-clearing pill (including tax) was 289 million yuan, showing a significant year-on-year increase of 52.28% [1] Strategic Initiatives - The company is actively promoting the Darentang Fast-Acting Rescue Heart Public Welfare Action and conducting promotional activities for the throat-clearing pill [1] - Initiatives such as the "Skin Health Theme Sales Project" and "Darentang Gastrointestinal Health China Tour" are being implemented for products like Jingwanhong and Weichang Anwan [1] - The company is accelerating the expansion of new retail channels, utilizing a dual-driven approach of B2C and O2O to explore new growth paths [1]